Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study-MedSci.cn

Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

Westerman, ME; Wood, CG

Wood, CG (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Urol, 1515 Holcombe,Unit 1373, Houston, TX 77030 USA.

ANNALS OF TRANSLATIONAL MEDICINE, 2020; 8 (16):

科室
- - 订阅+
  - 更多科室
工具
服务